EAST HILLS, N.Y.--(BUSINESS WIRE)--June 19, 2006--Pall Corporation (NYSE: PLL - News) announced today that Health Canada granted it clearance to market the Acrodose(TM) PL System. The new system gives blood centers the ability to pool and store whole blood derived platelets and conduct a single bacterial detection test that enhances patient safety and increases platelet availability. The resulting Acrodose(SM)Platelet provides hospitals with a transfusion-ready product that is safer than currently available whole blood derived platelets. It also reduces the cost burden to hospitals by eliminating the need for additional processing and testing.
